Miglitol is an oral alpha-glucosidase inhibitor used to improve glycemic control by delaying the digestion of carbohydrates. Miglitol inhibits the breakdown complex carbohydrates into glucose.
- Mechanism
- Curator reviewed
In contrast to sulfonylureas, miglitol does not enhance insulin secretion. The antihyperglycemic action of miglitol results from a reversible inhibition of membrane-bound intestinal a-glucoside hydrolase enzymes. Membrane-bound intestinal a-glucosidases hydrolyze oligosaccharides and disaccharides to glucose and other monosaccharides in the brush border of the small intestine. In diabetic patients, this enzyme inhibition results in delayed glucose absorption and lowering of postprandial hyperglycemia.
- Primary indication
- For use as an adjunct to diet to improve glycemic control in patients with non-insulin-dependent diabetes mellitus (NIDDM) whose hyperglycemia cannot be managed with diet alone.Curator reviewed · 2 structured indications
- Formula / weight
- C8H17NO5 · 207.2243 g/mol (avg)
- First approval
- United States, 1996
- Code names
- Bay m 1099
Resolves to
IBAQFPQHRJAVAV-ULAWRXDQSA-NSMILESOCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1COWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Miglitol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account